Magnesium Sulfate in Pregnancy and Postpartum

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT02317146
• Date of registration: 11/12/2014
• Prospective Registration: No
• Primary sponsor: Complejo Hospitalario Dr. Arnulfo Arias Madrid
• Public title: Magnesium Sulfate in Pregnancy and Postpartum MAG-PP
• Scientific title: A Novel Protocol for Postpartum Magnesium Sulfate in Severe Preeclampsia When the Woman Received Less That 8 Hours Before Delivery. Six Versus Twenty-four Hours Postpartum
• Date of first enrolment: November 2013
• Target sample size: 280
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02317146
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2/Phase 3

Countries of recruitment

Panama

Contacts

• Name: Roberto Lewis, MD
• Affiliation: Caja de seguro Social

Key inclusion & exclusion criteria

Inclusion Criteria:

Severe hypertensive disorder receiving magnesium sulfate prophylaxis for less than 8 hours
at birth.

Exclusion Criteria:

- Complications such as: HELLP syndrome, renal failure, eclampsia, retinal detachment,
cerebral edema, pulmonary edema, hypertensive encephalopathy.



Age minimum: 14 Years
Age maximum: 44 Years
Gender: Female

Health Condition(s) or Problem(s) studied

Severe Pre-eclampsia With Postnatal Complication

Intervention(s)

Drug: Magnesium Sulfate

Primary Outcome(s)

Seizure (Eclampsia) [Time Frame: 72 hours postpartum]

Secondary Outcome(s)

Persistent symptomatology [Time Frame: 24 hours postpartum]

Diuresis postpartum [Time Frame: 72 hours postpartum]

Secondary ID(s)

complejoh4

Source(s) of Monetary Support

Please refer to primary and secondary sponsors